Efficacy of topical gabapentin in women with primary macular amyloidosis: A side-by-side triple-blinded randomized clinical trial.
gabapentin
macular amyloidosis
pruritus
topical gabapentin
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
revised:
08
12
2023
received:
07
09
2023
accepted:
31
12
2023
medline:
31
1
2024
pubmed:
31
1
2024
entrez:
31
1
2024
Statut:
aheadofprint
Résumé
Primary cutaneous macular amyloidosis (PCMA) is a chronic pruritic cutaneous disease characterized by heterogeneous extracellular deposition of amyloid protein in the skin. This study aimed to evaluate the efficacy of topical 6% gabapentin cream for the treatment of patients with PCMA. In this triple-blind clinical trial, a total of 34 patients, who were diagnosed with PCMA, treated using two different strategies of topical gabapentin as the active group and vehicle cream as the control group. Pruritus score reduction in both groups was statistically significant compared with the baseline value (p < 0.001). There was a significant pigmentation score reduction in intervention group compared with control group after 1 month of the study (p < 0.001). The differences of pigmentation score changes between the groups were not significant at month 2 (p = 0.52) and month 3 (p = 0.22). The results of this study suggest that topical gabapentin cream may be effective as a topical agent in the treatment of pruritus associated with PCMA without any significant adverse effects. It is recommended to perform similar studies with a larger sample size and longer duration in both sexes.
Sections du résumé
BACKGROUND
BACKGROUND
Primary cutaneous macular amyloidosis (PCMA) is a chronic pruritic cutaneous disease characterized by heterogeneous extracellular deposition of amyloid protein in the skin.
AIMS
OBJECTIVE
This study aimed to evaluate the efficacy of topical 6% gabapentin cream for the treatment of patients with PCMA.
MATERIALS AND METHODS
METHODS
In this triple-blind clinical trial, a total of 34 patients, who were diagnosed with PCMA, treated using two different strategies of topical gabapentin as the active group and vehicle cream as the control group.
RESULTS
RESULTS
Pruritus score reduction in both groups was statistically significant compared with the baseline value (p < 0.001). There was a significant pigmentation score reduction in intervention group compared with control group after 1 month of the study (p < 0.001). The differences of pigmentation score changes between the groups were not significant at month 2 (p = 0.52) and month 3 (p = 0.22).
CONCLUSIONS
CONCLUSIONS
The results of this study suggest that topical gabapentin cream may be effective as a topical agent in the treatment of pruritus associated with PCMA without any significant adverse effects. It is recommended to perform similar studies with a larger sample size and longer duration in both sexes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Shumway NK, Cole E, Fernandez KH. Neurocutaneous disease: neurocutaneous dysesthesias. J Am Acad Dermatol. 2016;74(2):215-228.
Weidner T, Illing T, Elsner P. Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol. 2017;18(5):629-642.
Ahramiyanpour N, Akbari Z, Sarasyabi MS, Aflatoonian M, Saki N, Shafie'ei M. The therapeutic role of lasers in primary localized cutaneous amyloidosis: a systematic review. Lasers Med Sci. 2021;37:799-813.
Hamie L, Haddad I, Nasser N, Kurban M, Abbas O. Primary localized cutaneous amyloidosis of keratinocyte origin: an update with emphasis on atypical clinical variants. Am J Clin Dermatol. 2021;22(5):667-680.
Rinaldi G. The itch-scratch cycle: a review of the mechanisms. Dermatol Pract Concept. 2019;9(2):90-97.
Tanaka A, Arita K, Lai-Cheong J, Palisson F, Hide M, McGrath J. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009;161(6):1217-1224.
Taylor CP, Gee NS, Su T-Z, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29(3):233-249.
Ciceri P, Elli F, Brenna I, Volpi E, Brancaccio D, Cozzolino M. The calcimimetic calindol prevents high phosphate-induced vascular calcification by upregulating matrix GLA protein. Nephron Exp Nephrol. 2012;122(3-4):75-82.
Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain. 2000;85(3):405-414.
Maciel AAW, Cunha PR, Laraia IO, Trevisan F. Efficacy of gabapentin in the improvement of pruritus and quality of life of patients with notalgia paresthetica. An Bras Dermatol. 2014;89:570-575.
Thornsberry LA, English JC. Scalp dysesthesia related to cervical spine disease. JAMA Dermatol. 2013;149(2):200-203.
Hiom S, Patel GK, Newcombe RG, Khot S, Martin C. Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin. Br J Dermatol. 2015;173(1):300-302.
Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008;112(3):579-585.
Fang S, Shen X, Chen A-J, Li S, Shan K. Health-related quality of life in patients with primary cutaneous amyloidosis. PloS One. 2015;10(3):e0120623.
Reich A, Mędrek K, Szepietowski J. Four-item itch questionnaire-validation of questionnaire. Przegl Dermatol. 2012;99(5):600-604.
Brid T, Sacristán de Lama MP, González N, Baamonde A. Topical gabapentin as add-on therapy for trigeminal neuralgia. A case report. Pain Med. 2017;18(9):1824-1826.
Summey BT Jr, Yosipovitch G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther. 2005;18(4):328-332.
Anand S. Gabapentin for pruritus in palliative care. Am J Hosp Palliat Care. 2013;30(2):192-196.
Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a Calcium Channel (*). J Biol Chem. 1996;271(10):5768-5776.
Maneuf Y, Luo Z, Lee K, editorsα2δ and the mechanism of action of gabapentin in the treatment of pain. Seminars in Cell & Developmental Biology. Elsevier; 2006.
Yoon MH, Choi JI, Jeong SW. Spinal gabapentin and antinociception: mechanisms of action. J Korean Med Sci. 2003;18(2):255-261.
Aquino TMO, Luchangco KAC, Sanchez EV, Verallo-Rowell VM. A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus. Int J Dermatol. 2020;59(8):955-961.
Saki N, Ahramiyanpour N, Heiran A, Alipour S, Parvizi MM. Efficacy of topical dimethyl sulfoxide (DMSO) 50% solution vs tretinoin 0.5% cream in treatment of patients with primary macular amyloidosis: a split-side single-blinded randomized clinical trial. Dermatol Ther. 2020;33(3):e13305.